Emerson Electric (EMR) CEO granted 350,000 stock options in 5 tranches

Emerson Electric (EMR) reported an insider equity award to its President & CEO and Director, Surendralal Lanca Karsanbhai.

Rhea-AI Filing Summary

Emerson Electric (EMR) reported an insider equity award to its President & CEO and Director, Surendralal Lanca Karsanbhai. On 11/13/2025, he was granted a total of 350,000 employee stock options in five tranches of 70,000 each. All tranches become exercisable in five equal annual installments of 14,000 beginning on 11/13/2026 and expire on 11/13/2035.

The options carry exercise prices of $128.46, $160.575, $192.69, $224.805, and $256.92. Notes state that certain tranches are priced at 125%, 150%, 175%, and 200% of the grant‑date closing price. The grant was made under a shareholder‑approved plan and is exempt pursuant to Rule 16b‑3(d).

Insider Trade Summary

Grant/Award: 350,000 shares

Grant/Award 5 txns

Insider Karsanbhai Surendralal Lanca

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	70,000	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy)	70,000	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy)	70,000	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy)	70,000	$0.00	$0.00
Grant/Award	Employee Stock Option (Right to Buy)	70,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 350,000 contracts (Direct)

Footnotes (7)

1. F1. Grant of stock options under shareholder approved benefit plan exempt pursuant to Rule 16b-3(d).
2. F2. The Reporting person was awarded a total of 350,000 stock options on 11/13/2025 in 5 tranches of 70,000 stock options each, with each tranche having a different exercise price. Each of the 5 tranches of 70,000 stock options become exercisable in five equal annual installments of 14,000 each beginning on 11/13/2026.
3. F3. Price is not applicable to stock options received as incentive compensation.
4. F4. The exercise price is equal to 125% of the closing price of Issuer's common stock on the date of grant.
5. F5. The exercise price is equal to 150% of the closing price of Issuer's common stock on the date of grant.
6. F6. The exercise price is equal to 175% of the closing price of Issuer's common stock on the date of grant.
7. F7. The exercise price is equal to 200% of the closing price of Issuer's common stock on the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Emerson Electric (EMR) disclose in the Form 4?

A grant of 350,000 employee stock options to its President & CEO in five tranches of 70,000 each awarded on 11/13/2025.

When do the EMR CEO’s options vest and expire?

Each tranche vests in five equal annual installments of 14,000 beginning on 11/13/2026 and expires on 11/13/2035.

What are the exercise prices for the EMR option tranches?

The tranches have exercise prices of $128.46, $160.575, $192.69, $224.805, and $256.92.

How were certain EMR option exercise prices determined?

Notes indicate certain tranches are set at 125%, 150%, 175%, and 200% of the grant‑date closing price.

Under what rule/plan were the EMR options granted?

They were granted under a shareholder‑approved plan and are exempt under Rule 16b‑3(d).

Who is the reporting person in this EMR Form 4?

Surendralal Lanca Karsanbhai, Emerson’s President & CEO and a Director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Karsanbhai Surendralal Lanca

(Last) (First) (Middle)

C/O EMERSON ELECTRIC CO.

8027 FORSYTH BLVD.

(Street)

ST. LOUIS MO 63105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EMERSON ELECTRIC CO [ EMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$128.46	11/13/2025		A(1)		70,000		11/13/2026(2)	11/13/2035	Common Stock	70,000	(3)	70,000	D
Employee Stock Option (Right to Buy)	$160.575(4)	11/13/2025		A(1)		70,000		11/13/2026(2)	11/13/2035	Common Stock	70,000	(3)	70,000	D
Employee Stock Option (Right to Buy)	$192.69(5)	11/13/2025		A(1)		70,000		11/13/2026(2)	11/13/2035	Common Stock	70,000	(3)	70,000	D
Employee Stock Option (Right to Buy)	$224.805(6)	11/13/2025		A(1)		70,000		11/13/2026(2)	11/13/2035	Common Stock	70,000	(3)	70,000	D
Employee Stock Option (Right to Buy)	$256.92(7)	11/13/2025		A(1)		70,000		11/13/2026(2)	11/13/2035	Common Stock	70,000	(3)	70,000	D

Explanation of Responses:

1. Grant of stock options under shareholder approved benefit plan exempt pursuant to Rule 16b-3(d).

2. The Reporting person was awarded a total of 350,000 stock options on 11/13/2025 in 5 tranches of 70,000 stock options each, with each tranche having a different exercise price. Each of the 5 tranches of 70,000 stock options become exercisable in five equal annual installments of 14,000 each beginning on 11/13/2026.

3. Price is not applicable to stock options received as incentive compensation.

4. The exercise price is equal to 125% of the closing price of Issuer's common stock on the date of grant.

5. The exercise price is equal to 150% of the closing price of Issuer's common stock on the date of grant.

6. The exercise price is equal to 175% of the closing price of Issuer's common stock on the date of grant.

7. The exercise price is equal to 200% of the closing price of Issuer's common stock on the date of grant.

Remarks:

	/s/ John A. Sperino, Attorney-in-Fact for Surendralal Lanca Karsanbhai	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.